Novo Nordisk to cut US list prices of two insulin products by more than 70%-February 2024-www.financetom.com

Novo Nordisk to cut US list prices of two insulin products by more than 70%

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Novo Nordisk to cut US list prices of two insulin products by more than 70%

Dec 5, 2024 5:54 AM

COPENHAGEN, Dec 5 (Reuters) - Danish drug maker Novo

Nordisk said on Thursday it had plans to reduce the

U.S. list prices of two insulin products by more than 70% from

January of 2026.

Previous page： Purple Biotech Moves NT219 Into Phase 2 Trial Aimed at Overcoming Tumor Resistance in Head, Neck Cancer Therapies Next page： Espey Mfg. & Electronics Names Kaitlyn O'Neil as Principal Financial Officer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Purple Biotech Moves NT219 Into Phase 2 Trial Aimed at Overcoming Tumor Resistance in Head, Neck Cancer Therapies

Feb 18, 2025

08:41 AM EST, 02/18/2025 (MT Newswires) -- Purple Biotech ( PPBT ) said Tuesday it is advancing its drug candidate NT219 into a phase 2 clinical trial aimed at overcoming tumor resistance in therapies for recurring metastatic squamous cell cancer of the head and neck. The study will evaluate the safety and efficacy of NT219 in combination with standard therapies...

Espey Mfg. & Electronics Names Kaitlyn O'Neil as Principal Financial Officer

Feb 18, 2025

08:44 AM EST, 02/18/2025 (MT Newswires) -- Espey Mfg. & Electronics Corp. ( ESP ) said Tuesday it has named Kaitlyn O'Neil as principal financial officer and treasurer, effective Feb. 15. The appointment comes after the retirement of Katrina Sparano, who served as chief financial officer of the company. ...

Expeditors International of Washington's Q4 Earnings, Revenue Rise

Feb 18, 2025

08:49 AM EST, 02/18/2025 (MT Newswires) -- Expeditors International of Washington ( EXPD ) reported Q4 earnings Tuesday of $1.68 per diluted share, compared with $1.09 a year earlier. Analysts surveyed by FactSet expected $1.43. Revenue for the quarter ended Dec. 31 was $2.95 billion, compared with $2.28 billion a year earlier. Analysts surveyed by FactSet expected $2.79 billion. Shares...

Septerna Discontinues Phase 1 Trial of SEP-786 for Hypoparathyroidism; Shares Fall Pre-Bell

Feb 18, 2025

08:44 AM EST, 02/18/2025 (MT Newswires) -- Septerna ( SEPN ) shares were down sharply premarket Tuesday after the company said it has discontinued a phase 1 clinical trial of SEP-786 for the potential treatment of hypoparathyroidism in healthy volunteers. The company said the decision follows two unanticipated severe events of elevated unconjugated bilirubin in a portion of the trial,...